|
Congressional:
House Passes One Big Beautiful Bill Act
On Thursday morning, the House voted to advance the One Big Beautiful Bill Act in a 215-214 vote. No Democrats supported the measure, and two Republicans, Thomas Massie (R-KY) and Warren Davidson (R-OH), opposed it, while Andy Harris (R-MD) voted "present." The legislative package combines recommendations from 11 House committees that were instructed to find a minimum amount of savings or spend a maximum amount of money to implement their policies under the fiscal 2025 budget resolution (H. Con. Res. 14) that the House and Senate passed last month. On Wednesday, the House Rules Committee held a 21-hour markup and passed a 42-page manager's amendment along with the bill, which included additional tax cuts, health care provisions, and hundreds of billions of dollars in new funding for the military and border security.
The measure proposes sweeping reforms to health reimbursement arrangements (HRAs), health savings accounts (HSAs), Medicaid eligibility, and the Affordable Care Act (ACA). It would codify a 2019 Trump-era rule, renaming individual coverage HRAs as “CHOICE” arrangements and making them compliant with ACA coverage standards. The bill also expands HSA usage: doubling contribution limits for lower-income earners, covering fitness expenses and direct primary care payments, and allowing greater flexibility in enrollment, eligibility, and qualified expenses.
The bill would also make significant changes to Medicaid. It imposes nationwide work requirements for beneficiaries aged 19–64, effective on December 31, 2026, rather than a January 1, 2029, start as proposed in the initial version of the package, with exemptions for vulnerable populations. States would be responsible for verifying compliance and could disenroll noncompliant enrollees after notice. The bill ends bonus funding for non-expanding states that fail to adopt expansion by 2026, and mandates cost-sharing for ACA expansion enrollees above the poverty line. It also tightens eligibility through more frequent checks, asset limits, and interstate enrollment monitoring. Federal funding would be restricted for gender transition procedures, abortion-related services (with exceptions), and erroneous payments.
The bill also includes several reforms to the Affordable Care Act (ACA) and Medicare. It imposes stricter enrollment verification and limits premium tax credit eligibility to select noncitizens, barring Deferred Action for Childhood Arrivals (DACA) recipients and those earning below the poverty line while awaiting Medicaid access. The bill would appropriate funds for cost-sharing reductions (CSRs) for plan years beginning on or after January 1, 2026, and specifies that funds may not be used for payments to qualified health plans that include coverage of abortion services (with exceptions). For Advanced Premium Tax Credits (APTCs), the bill permits the IRS to recapture excess APTC payments without limitation.
Changes to Medicare include adjusting physician payments by inflation and delinking pharmacy benefit manager (PBM) compensation from drug prices. It pauses the nursing home staffing rule through 2034, restricts ACA plan designs, and automatic enrollments. It also delays Medicaid hospital cuts and limits PBM spread pricing. The measure would also revise the Medicare physician payment formula by linking annual updates to the Medicare Economic Index, with rates increasing by 75% of the index’s growth in 2026 and 10% in subsequent years. It would also eliminate a scheduled policy to create a separate conversion factor for doctors in advanced alternative payment models, undoing changes made by the 2015 Medicare Access and CHIP Reauthorization Act.
The legislation now heads to the Senate, where Republican Senators are expected to put their own stamp on the legislation before sending it back to the House for final passage. Congressional leadership and President Trump have stated that their goal is to enact the bill into law by Independence Day.
Senate Appropriations Committee Holds Hearing on HHS Proposed Budget with Secretary Kennedy
On Tuesday, the Labor-HHS-Education Subcommittee of the Senate Appropriations Committee held a hearing to examine the proposed fiscal year 2026 Department of Health and Human Services (HHS) budget, with HHS Secretary Robert F. Kennedy Jr. testifying. During the hearing, Secretary Kennedy defended HHS’s reorganization as a necessary response to bureaucratic inefficiency and waste, aiming to redirect resources from administrative overhead toward direct health improvements. He emphasized a personal commitment to addressing chronic disease, addiction, rural health, and affordability of prescription drugs. Kennedy also stated that no essential research or services were being eliminated, only streamlined for effectiveness. Republicans largely supported Kennedy’s efforts to downsize HHS, reduce administrative costs, and eliminate redundancies. Republicans also emphasized concerns over National Institutes of Health (NIH) indirect funding misuse, the need for efficiency in research spending, preserving rural health and energy assistance programs, and continuing biomedical innovation. Democrats expressed concern over unauthorized cuts to HHS programs, including NIH research, Head Start, Medicaid, and substance use treatment. Democrats were largely critical of HHS’s lack of transparency, impounding funds Congress had appropriated, stating that these actions risked undermining bipartisan progress in public health and scientific leadership. Read Mehlman’s hearing summary here.
Senate Appropriations Committee Holds Hearing on FDA Proposed Budget with Commissioner Makary
On Thursday, the Senate Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies held a hearing on the President’s fiscal year 2026 budget request for the Food and Drug Administration (FDA), with FDA Commissioner Marty Makary testifying. During the hearing, Makary told members that the Trump administration proposes a $6.8 billion FDA budget for fiscal 2026, composed of $3.2 billion in taxpayer funds and $3.6 billion in user-fee program revenues paid by drug and device makers. Ranking Member Patty Murray (D-WA) criticized the proposed budget, stating, “You are now testifying that the budget proposes to slash FDA by more than 11 percent; that’s actually news to all of us, and I’ll tell you right now, it is not going to fly.” Democrats and Republicans also pressed Makary on the impact of the Trump administration’s staff cuts. Full Committee Chair Susan Collins (R-ME) stated her concern about the “downstream impact of delays on patients suffering from debilitating rare diseases.” Makary testified that the reductions in force and early retirements at the FDA have not impacted critical operations, like drug approvals or food safety inspections. Makary also emphasized that the agency was on track to meet all the prescription drug user fee targets Congress has set for it. Read Mehlman’s hearing summary here.
Notable Bills Introduced:
Representatives Khanna, Luna, Kaptur and Biggs Introduce Bill to Codify Trump's Executive Order to Lower Prescription Drug Costs
On Tuesday, Representatives Ro Khanna (D-CA), Anna Paulina Luna (R-FL), Marcy Kaptur (D-OH), and Andy Biggs (R-AZ) introduced the bipartisan Global Fairness in Drug Pricing Act to codify the core provisions of President Trump’s Executive Order into law. The legislation would direct HHS to propose rulemaking that imposes most-favored-nation price targets and authorize the FDA to consistently grant importation waivers for prescription drugs from countries with strong safety records and lower costs. Read the press release here and the bill here.
Senators Barrasso, Heinrich Introduce Bipartisan Bill to Encourage Development of Life-Saving Cures
On Thursday, Senators John Barrasso (R-WY) and Martin Heinrich (D-NM) introduced bipartisan legislation to make it easier to develop new life-saving cures for Americans affected by rare diseases. The Optimizing Research Progress Hope and New (ORPHAN) Cures Act supports the development of breakthrough treatments and cures through the continued investment in American innovation. Read the press release here and the bill here.
Senators Introduce Bipartisan Bill to Ease the Financial Burden of Pregnancy, Childbirth
On Wednesday, Senators Cindy Hyde-Smith (R-MS), Tim Kaine (D-VA), Josh Hawley (R-MO), and Kirsten Gillibrand (D-NY) introduced bipartisan legislation to insulate expecting parents from the high cost of pregnancy and childbirth. The Supporting Healthy Moms and Babies Act would prevent cost-sharing requirements for prenatal, childbirth, neonatal, perinatal, or postpartum health care for Americans with private health insurance. Read the press release here and the bill here.
Representative DelBene, Colleagues Introduce Prior Authorization Legislation
On Wednesday, Representatives Suzan DelBene (D-WA), Mike Kelly (R-PA), Ami Bera, M.D. (D-CA), and John Joyce, M.D. (R-PA), introduced an updated Improving Seniors’ Timely Access to Care Act. The bipartisan legislation would streamline and modernize the prior authorization process under Medicare Advantage. Specifically, the bill would establish an electronic prior authorization process for Medicare Advantage plans, increase transparency around Medicare Advantage prior authorization requirements, and clarify HHS’ authority to establish timeframes for e-prior authorization requests. Senators Roger Marshall, M.D. (R-KS) and Mark Warner (D-VA) introduced the companion bill in the Senate. Read the press release here and the bill here.
Senator Peters, Colleagues Introduce Bipartisan Bill to Improve Visibility and Coordination for Essential Medicine Supply Chains
Late last week, on Friday, Senators Gary Peters (D-MI), James Lankford (R-OK), Joni Ernst (R-IA), Tom Cotton (R-AR), Tim Kaine (D-VA), Angus King (I-ME), and Rick Scott (R-FL) introduced bipartisan legislation to improve federal coordination and visibility for the essential medicine supply chains, from key ingredients needed to manufacture essential medicines to their distribution in hospitals and pharmacies. The Mapping America’s Pharmaceutical Supply (MAPS) Act would proactively identify and address supply chain weaknesses that could lead to shortages or other challenges in future public health crises. Read the press release here and the bill here.
Executive Branch:
CMS Announces Increase in Medicare Advantage Audits
On Wednesday, the Centers for Medicare & Medicaid Services (CMS) announced a significant expansion of its auditing efforts for Medicare Advantage (MA) plans. Beginning immediately, CMS will audit all eligible MA contracts for each payment year in all newly initiated audits and invest additional resources to expedite the completion of audits for payment years 2018 through 2024. Dr. Mehmet Oz, CMS Administrator stated that “While the Administration values the work that Medicare Advantage plans do, it is time CMS faithfully executes its duty to audit these plans and ensure they are billing the government accurately for the coverage they provide to Medicare patients.” CMS stated it would "invest additional resources" to increase the pace of audits and rely on "enhanced technology" to review medical records and flag questionable diagnoses and will increase its team of medical coders from 40 to about 2,000 by September 1. It aims to increase its audits from 60 Medicare Advantage plans per year to approximately 550. It will also increase the number of records it will audit per plan. Read the press release here.
Departments of Labor, Health and Human Services, Treasury Announce RFI and Guidance on Healthcare Price Transparency
On Thursday, the departments of Labor, Health and Human Services, and the Treasury jointly issued a Request for Information seeking public input on how to improve prescription drug price transparency. The RFI seeks input regarding the prescription drug price disclosure requirements, including information on existing prescription drug file data elements and information on implementation generally, such as the ability of health plans to access necessary data for reporting, as well as state approaches and innovation. The agencies also released updated guidance for health plans and issuers that sets an applicability date for publishing an enhanced technical format for disclosures. These improvements are designed to eliminate duplicative data and make cost information easier for consumers to understand and use.
Separately, the Centers for Medicare & Medicaid Services (CMS) released new guidance, available on the Hospital Price Transparency resources website, to strengthen the Hospital Price Transparency requirements, requiring hospitals to post the actual prices of items and services, not estimates. CMS also issued its own RFI to gather public feedback on how to boost hospital compliance and enforcement and ensure data shared is accurate and complete. Read the press release here.
White House Releases Make America Healthy Again (MAHA) Commission Report
On Thursday, President Trump released the Make America Healthy Again (MAHA) Commission Report at the White House, joined by Agriculture Secretary Brooke Rollins. In February, Trump established the MAHA Commission, chaired by Health & Human Services (HHS) Secretary Robert F. Kennedy Jr., and tasked it with looking into the root causes of America’s health crisis, focusing initially on childhood chronic diseases. The commission’s first instruction was to conduct an assessment summarizing its findings on childhood chronic diseases within 100 days and then produce a strategy to improve children’s health in its first 180 days. The report stated that the childhood health crisis is “likely being driven by combination of factors, including the food children are eating, the chemicals they are exposed to, the medications they are taking and various changes to their lifestyle and behavior, particularly those related to physical activity, sleep and the use of technology.” The report vows to "begin reversing the childhood chronic disease crisis" during this administration beginning with reassessing the childhood vaccine schedule and studying ultra-processed foods and the use of pesticides in commercial farming. The commission is expected to deliver a strategy within the next 100 days. Read the press release here and the report here.
FDA to Narrow Approval of COVID-19 Shots for Healthy Individuals Under 65
On Tuesday, the Food and Drug Administration (FDA) Commissioner Martin Makary and Vinay Prasad, director of the Center for Biologics Evaluation and Research, announced a new framework for COVID-19 vaccines for healthy people under age 65 in a New England Journal of Medicine article. The article stated that the FDA anticipates the need for randomized, controlled trial data evaluating clinical outcomes of the COVID-19 booster for healthy people under age 65, before Biologics License Applications can be granted. The change comes ahead of an FDA Vaccines and Related Biological Products Advisory Committee meeting on Thursday, at which the panel will make recommendations for the strain selection for the 2025-2026 COVID-19 vaccine. The panel routinely makes its strain selection recommendation in the spring to prepare for the fall, on a similar timeline as the annual flu vaccine program. Read the article here.
|